IDH1 and acute myeloid leukemia: Emadi’s group also uncovered that reducing glutamine resulted in a decrease of the metabolite 2-hydroxybutyric acid (2-HG) and thus inhibited the proliferation of AML cells with isocitrate dehydrogenase (IDH) mutations [18].